Daniel LeMay (a pseudonym) is the military whistleblower behind The Remdesivir Papers. Published on Friday at The Gateway Pundit, the 5,400-word report tells the “alarming story of profit-driven clinical care which is well removed from the interests of the patients and their loved ones,” LeMay tells AFN, emphasizing that his views do not reflect those of the Department of Defense or any associated entity.
In the immediate wake of the coronavirus pandemic, military treatment facilities and other institutions around the country embarked on a journey in early 2020 to treat the virus with remdesivir, a drug with a deadly history. Past clinical trials to demonstrate the efficacy of remdesivir have resulted in death. For example, the use of remdesivir in a trial of four investigational therapies for Ebola in the Democratic Republic of Congo resulted in the highest mortality rate among participants.
Interestingly, the military still decided the controversial drug was worth trying for the treatment of COVID-19. “Even the foundational study on remdesivir is easily recognizable as intentionally skewed,” LeMay argues.
As the report states, “[Clinical trial NCT04280705] is problematic due to multiple confounding variables that appear to exist intentionally to present a positive outcome for the remdesivir group.”
LeMay responds, “We're not talking about a case of bad math because their findings should've been thoroughly reviewed and replicated as those components are essential to the scientific process.”
Across the Department of Defense, 64% of COVID patients who died between March 2020 and March 2024 were treated with remdesivir. Considering the lethality of remdesivir, should military leadership be held accountable for their endorsement of the controversial drug?
“That’s the dilemma,” LeMay explains. “It's reasonable to call for resignations, but no one will step down.”
“The oath, if I remember correctly, is loyalty to the Constitution first and foremost,” he continues, tongue-in-cheek. “Closely following is obedience to those appointed over you. But if those orders are unconstitutional, then a person of integrity is obligated to reject them.”
As for the Constitution's promise of life and liberty, he contends many service members in fact received “deadly mandates, isolation, and widespread suppression of our fundamental freedom of movement.”
LeMay argues that “it's also reasonable to label this ordeal criminal negligence of the highest order – but no one is going to jail. [Clealy] there are those who are above the justice system.”
Multiple email inquiries were made to military treatment facilities around the country, seeking information about the use of a deadly drug in treatment trials. A Freedom of Information Act (FOIA) request was also filed with to U.S. Army Medical Research and Development Command (USAMRDC) and has been assigned a case number. In addition, Congressman Clay Higgins (R-Louisiana) sent a letter to Secretary of Defense (SECDEF) Lloyd Austin and others to learn more about the treatment of COVID-19 with remdesivir in personnel affiliated with the Department of Defense.
“I've seen and heard the SECDEF in front of Congress, being questioned and providing very unimpressive non-answers,” the whistleblower tells AFN. “The lack of transparency and willingness to be dishonest publicly, coupled with obstructing meaningful inquiries, gives me zero confidence in his and others' ability to effectively lead.”
He adds: “The DoD has made it clear that it's above oversight.”
LeMay, an avowed Christian, recognizes it has become "wildly unfashionable, especially in recent years" for individuals to claim Jesus as their "bottom line."
“[But] He is my bottom line, my boldness, my victory over fear,” LeMay emphasizes. Just as Hezekiah placed the words of Sennacherib, king of Assyria, before the Lord God, “I too will place before Him the words of anyone suppressing the truth and those who speak it,” he adds.
“Jesus is the Rock of my salvation and he who falls upon Him will be broken, but he who He falls upon will be dashed to pieces. Amen.”
